34^th Global Ophthalmologists Annual meeting August 24-25, 2020 London, UK

Biography:

Being a fellow (FCPS ) from College of Physicians and Surgeons Pakistan, ICOphth part 1&2 from International Council Of Ophthalmology England, more than 14 published research papers 9 of them published in USA, conference presentations. More than 12 years teaching undergraduate as well as post graduate students , more than 18 yrs of national and international experience, having good command over phaco surgery, medical retina etc. Presently working as assistant professor at Indus Medical College, Pakistan and consultant ophthalmologist at Mohammad Dossary Hospital, Khobar.

Abstract:

Purpose: To evaluate the effect of topical bromfenac nonsteroidal anti-inflammatory drug (NSAID) in the treatment of acute central serous chorioretinopathy at our facility.

 Introduction: CSC is a disorder that is mostly idiopathic, characterized by a serous detachment of the neurosensory retina at the macula, which is caused by active retinal pigment epithelial leakage. Although the exact pathophysiology of CSC has not been clearly elucidated, the primary abnormality leading to RPE disruption and leakage is thought to cause increase choroidal permeability. Studies using different imaging techniques have revealed the possible causes of abnormal permeability of the inner choroid. Ischemia and inflammation might lead to exudative changes within the choroid and the subsequent changes at the RPE. Topical bromfenac, ketorolac, nepafenac and diclofenac all belong to the NSAIDs class of medications. As an anti-inflammatory class, they function by inhibiting the enzyme cyclooxygenase, which blocks the synthesis of prostaglandins. A reduction in prostaglandin formation results a decrease in inflammation. It appears that the principle pathway involved in pain and inflammation is the cycloxygenase-2 pathway where nonsteroidal anti-inflammatory drugs (NSAIDs) seems to play a significant role.

Material and Method: This is an interventional study conducted at Indus Medical College Hospital, Tando Mohammad Khan, from February to September 2017 and includes 11 patients. Patients with acute CSC were included while those with chronic or recurrence were excluded. Careful history taken regarding sensitivity to bromfenac or any other NSAIDs. All patients were diagnosed as having acute CSC relying upon visual acuity by standard Snellen chart, dilated fundus exam using slit lamp with 90D lens and OCT (optical coherence tomography) findings. All patients were treated by bromfenac topical drops twice daily. Patients followed on 5th day, 10th day and 30th day. Vision was recorded, dilated fundoscopy and OCT performed on each visit.

All 11 patients were male (Table 1), divided into 3 age groups i.e. group A(21-30yrs) includes 6(54.54%) patients, group B (31- 40 yrs) includes 4(36.36%) patients and group C (41-50 yrs ) includes 1(9.09%) patient  (Table 2). 4(36.36%)were right eyes, 7(63.63%)were left(Table 3). Vision recorded using standard Snellen chart, 4(36.36%)patients having vision 0.4, 3 (27.27%)were 0.2, 2 (18.18%) were having 0.1 while remaining 2 (18.18%) were recorded as CF at 1 meter (Table 4). Macular thickness recorded using OCT, patients again divided into 3 groups on OCT findings, group 1, 5(45.45%) patients having macular thickness between 422-485 microns, group 2, 4(36.36%) patients between 535-565 microns while group 3, includes 2(18.18.%) patients having thickness between 612-644 microns (Table 5). All 11 patients received topical bromfenac, one drop twice daily to treat acute CSC for 10 days and monitor for 1 month.

Results: This is an interventional study includes 11 patients who were diagnosed with acute CSC and followed from the day of presentation to 30th day. .All 11 patients were underwent intervention by using topical bromfenac eye drop, one drop twice daily for up to 30th day. Macular thickness and visual acuity recorded from the day of onset up to 30th day.

In group 1, the macular thickness (CFT) improve from 422-485 microns at onset to 317-382 microns on 5th day becomes 246-295 on 10 day while 210-226 on 30th day. Vision improved from 0.4 to 0.7 at 5th day, improved to 0.8 on 10th day and remained same on 30th day.

In group 2, the CFT reduced from 535-565 microns at onset to 401-440 microns on 5th day becomes 318-310 on 10th day and on 30th day it was 221-232 microns with improvement in visual acuity which was 0.2 at onset to 0.6 at 5th day, 0.7 on 10th day and improved to 0.8 on 30th day.

In group 3 the CFT reduced from 612-644 microns at onset to 560-595 microns on 5th day, 366-388microns on 10th day while 227-252 microns on 30th day. Visual acuity improved from CF at onset to 0.4 on 5th day, 0.6 on 10th day and improved to 0.7 on 30th day.

Conclusion: This treatment modality is safe, affordable and easily available all over the world with early rehabilitation of acute CSC patients.